These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 6415316)

  • 21. Occurrence of cytosolic protein and phosphoprotein changes in human colon tumor cells with the development of resistance to mitomycin C.
    Taylor CW; Brattain MG; Yeoman LC
    Cancer Res; 1985 Sep; 45(9):4422-7. PubMed ID: 3928156
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interferons modify in vitro proliferation of human bladder transitional cell carcinoma in the presence of doxorubicin and mitomycin C.
    Okamoto E; Kinne RK; Sökeland J
    J Urol; 1996 Oct; 156(4):1492-5. PubMed ID: 8808915
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Caffeine sensitive recovery of mitomycin C treated mouse P-388 cells.
    Orstavik J
    Acta Pathol Microbiol Scand B Microbiol Immunol; 1972; 80(6):900-4. PubMed ID: 4509396
    [No Abstract]   [Full Text] [Related]  

  • 24. Modulating effect of mitomycin or cisplatin on lymphokine-activated killer cell proliferation and antitumor activity to bladder cancer cell lines in vitro.
    Wang ZP; Qing DS; Shi BG; Chen YR; Liu GD
    Zhongguo Yao Li Xue Bao; 1998 Jul; 19(4):369-72. PubMed ID: 10375787
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [gamma-Glutamylcysteine synthetase and chemosensitivity].
    Nishio K; Kurokawa H; Ishida T; Fukuoka K; Saijo N
    Gan To Kagaku Ryoho; 1997 Feb; 24(4):418-23. PubMed ID: 9063478
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mode of action of polyethylene glycol 6000 in potentiating the in vitro generation of antitumor cytotoxicity by MOPC-315 tumor bearer spleen cells.
    Mokyr MB; Przepiorka D; Dray S
    Cancer Res; 1982 Jul; 42(7):2537-43. PubMed ID: 6805940
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antitumor activity of albendazole against the human colorectal cancer cell line HT-29: in vitro and in a xenograft model of peritoneal carcinomatosis.
    Pourgholami MH; Akhter J; Wang L; Lu Y; Morris DL
    Cancer Chemother Pharmacol; 2005 May; 55(5):425-32. PubMed ID: 15565325
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Phase I study of KW2083 7-N-(p-hydroxyphenyl) mitomycin C].
    Gan To Kagaku Ryoho; 1982 Oct; 9(10):1844-50. PubMed ID: 7184379
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Growth inhibition and cell enlargement in P-388 cells treated with mitomycin C.
    Orstavik J
    Acta Pathol Microbiol Scand B Microbiol Immunol; 1972; 80(4):519-24. PubMed ID: 4509187
    [No Abstract]   [Full Text] [Related]  

  • 30. [Pharmacokinetics of mitomycin C and its derivative (KW-2083)].
    Fujita H
    Gan To Kagaku Ryoho; 1982 Aug; 9(8):1362-73. PubMed ID: 6820913
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enhanced antitumor activity of irofulven in combination with thiotepa or mitomycin C.
    Kelner MJ; McMorris TC; Rojas RJ; Trani NA; Estes L
    Cancer Chemother Pharmacol; 2002 May; 49(5):412-8. PubMed ID: 11976836
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Cell cycles of cancer cells and chemotherapy--flow cytometric observation of the effects of chemotherapeutic agents on cell kinetics of cultured human lung cancer cells].
    Shimizu T
    Hokkaido Igaku Zasshi; 1983 Sep; 58(5):467-82. PubMed ID: 6662482
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cytotoxic activity of 7-N-(2-((2-(-gamma-L-glutamylamino)- ethyl)dithio)ethyl)-mitomycin C and metabolites in cell lines with different resistance patterns.
    Dirix LY; Gheuens EE; van der Heyden S; van Oosterom AT; De Bruijn EA
    Anticancer Drugs; 1994 Jun; 5(3):343-54. PubMed ID: 7919460
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Normal bronchial epithelial cell expression of glutathione transferase P1, glutathione transferase M3, and glutathione peroxidase is low in subjects with bronchogenic carcinoma.
    Crawford EL; Khuder SA; Durham SJ; Frampton M; Utell M; Thilly WG; Weaver DA; Ferencak WJ; Jennings CA; Hammersley JR; Olson DA; Willey JC
    Cancer Res; 2000 Mar; 60(6):1609-18. PubMed ID: 10749130
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Contaminants of PC-SPES are not responsible for cytotoxicity in human small-cell lung carcinoma cells.
    Sadava D; Winesburg J
    Cancer Lett; 2005 Apr; 220(2):171-5. PubMed ID: 15766592
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Re-evaluation of tumor-specific cytotoxicity of mitomycin C, bleomycin and peplomycin.
    Sasaki M; Okamura M; Ideo A; Shimada J; Suzuki F; Ishihara M; Kikuchi H; Kanda Y; Kunii S; Sakagami H
    Anticancer Res; 2006; 26(5A):3373-80. PubMed ID: 17094455
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effect of functional groups on reduction and activation of quinone bioreductive agents by DT-diaphorase.
    Fourie J; Oleschuk CJ; Guziec F; Guziec L; Fiterman DJ; Monterrosa C; Begleiter A
    Cancer Chemother Pharmacol; 2002 Feb; 49(2):101-10. PubMed ID: 11862423
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase II trial of mitomycin, vinblastine, and cisplatin (MVP) in non-small cell bronchogenic carcinoma.
    Schulman P; Budman DR; Weiselberg L; Vinciguerra V; Degnan TJ
    Cancer Treat Rep; 1983 Oct; 67(10):943-5. PubMed ID: 6684988
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development and application of a sensitive enzyme immunoassay for 7-N-(p-hydroxyphenyl)mitomycin C.
    Fujiwara K; Nakamura H; Kitagawa T; Nakamura N; Saito A; Hara K
    Cancer Res; 1984 Sep; 44(9):4172-6. PubMed ID: 6430558
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Overcoming mitomycin C resistance with semisynthetic derivatives.
    Brattain MG; Willson JK; Long BH; Chakrabarty S; Yeoman LC; Stringfellow DA
    Prog Clin Biol Res; 1986; 223():63-79. PubMed ID: 3101070
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.